Silence Therapeutics (NASDAQ:SLN) Releases Earnings Results, Misses Expectations By $0.13 EPS

Silence Therapeutics (NASDAQ:SLN) issued its quarterly earnings results on Thursday. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.13), FiscalAI reports. Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%.

Silence Therapeutics Trading Up 0.2%

NASDAQ:SLN traded up $0.04 during mid-day trading on Thursday, hitting $19.82. The stock had a trading volume of 346,791 shares, compared to its average volume of 1,092,960. The company has a 50 day simple moving average of $14.46 and a 200-day simple moving average of $9.61. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -15.48 and a beta of 1.34. Silence Therapeutics has a 52 week low of $4.19 and a 52 week high of $19.86.

Wall Street Analysts Forecast Growth

SLN has been the subject of a number of research reports. William Blair downgraded shares of Silence Therapeutics from an “outperform” rating to a “hold” rating in a report on Monday, October 19th. Jefferies Financial Group downgraded shares of Silence Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 price objective for the company. in a research report on Monday, October 19th. HC Wainwright lowered shares of Silence Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $75.00 to $20.00 in a research note on Wednesday, October 21st. Chardan Capital cut shares of Silence Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a report on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $24.00.

Silence Therapeutics Company Profile

Silence Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce production of specific disease-related proteins. Its proprietary mRNAi GOLD platform is designed to create small interfering RNA (siRNA) medicines, including treatments that target genes expressed in the liver. The company’s research and development programs have included zerlasiran, which targets lipoprotein(a), a risk factor for cardiovascular disease, and divesiran, investigated for blood disorders.